参考文献

［1］Siegel R L，Miller K D，Jemal A.Cancer statistics，2015［J］.CA Cancer J Clin，2015，65（1）：5－29.

［2］Johnson D H，Schiller J H，Bunn P A，et al.Recent clinical advances in lung cancer management［J］.J Clin Oncol，2014，32（10）：973－982.

［3］Alberg A J，Brock M V，Ford J G，et al.Epidemiology of lung cancer：Diagnosis and management of lung cancer，3rd ed：American College of Chest Physicians evidencebased clinical practice guidelines［J］.Chest，2013，143（5Suppl）：e1S－29S.

［4］Howlader N，Noone A M，Krapcho M，et al.SEER Cancer Statistics Review，1975—2012，based on November 2014SEER data submission，posted to the SEER web site，April 2015.Bethesda，MD：National Cancer Institute，2015.

［5］Thun M J，Carter B D，Feskanich D，et al.50－year trends in smoking related mortality in the United States［J］.N Engl J Med，2013，368（4）：351－364.(https://www.daowen.com)

［6］Shiels M S，Gibson T，Sampson J，et al.Cigarette smoking prior to first cancer and risk of second smoking－associated cancers among survivors of bladder，kidney，head and neck，and stage I lung cancers［J］.J Clin Oncol，2014，32（35）：3989－3995.

［7］Aberle DR，Adams AM，Berg CD，et al.Reduced lung－cancer mortality with lowdose computed tomographic screening.N Engl J Med，2011，365（5）：395－409.

［8］Lindeman N I，Cagle P T，Beasley M B，et al.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors：Guideline from the College of American Pathologists，International Association for the Study of Lung Cancer，and Association for Molecular Pathology［J］.J Thorac Oncol，2013，8（7）：823－859.

［9］Martins R G，D'Amico T A，Loo BW，Jr.，et al.The management of patients with stageⅢA non－small cell lung cancer with N2mediastinal node involvement［J］.J Natl Compr Canc Netw，2012，10（5）：599－613.

［10］Rosenzweig K E，Chang J Y，Chetty I J，et al.ACR appropriateness criteria nonsurgical treatment for non－small－cell lung cancer：poor performance status or palliative intent［J］.J Am Coll Radiol，2013，10（9）：654－664.